Sakakibara Shan Riku sold $786K of BLLN

Sakakibara Shan Riku (Chief Product Officer) sold 8,000 shares of BillionToOne, Inc. (BLLN) at an average of $98.22 ($96.45–$100.00, $0.79M total) across 2 trades on 2026-06-08 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Sakakibara Shan Riku
Published Jun 11, 2026, 12:36 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 11, 2026, 1:00 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BLLN
Neutral
high confidence
Mentioned
$BLLN
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLLNNeutralLow
01

Why it matters

The only new information is the size/date/price range of the CPO’s open-market sale and that it was executed under a pre-arranged 10b5-1 plan.

02

Market read

This is a routine insider-sale filing; it can marginally influence sentiment but does not provide new fundamental drivers in the text.

03

What to watch

Traders may overreact to insider sales; without concurrent guidance, trial, or contract updates, the signal is typically weak.

Relevance 4/10Novelty 2/10Timing: Filed 2026-06-10 for a 2026-06-08 sale.

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for BillionToOne, Inc.

Company-level read

Ticker impact

$BLLNNeutralHigh confidence
Context

SEC Form 4 shows BLLN CPO Sakakibara Shan Riku sold 8,000 shares (~$785.8K) via an open-market sale under a 10b5-1 plan.

Expected impact

Low likelihood of sustained price impact; any reaction is likely short-lived unless accompanied by other company-specific news.

Evidence & confidence

The filing is a Form 4 insider transaction with a stated pre-arranged 10b5-1 plan and no accompanying operational/regulatory/financial catalyst in the text.

Market effects

No sector read-through; this is company-specific insider liquidity rather than a sector/regulatory development.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, it may reflect scheduled diversification rather than bearish expectations.

Key entities

  • BillionToOne, Inc.

    Company whose insider transaction is disclosed on SEC Form 4.

  • Sakakibara Shan Riku

    Chief Product Officer who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

Why is BillionToOne stock sliding today?

BillionToOne stock fell 6.2% in pre-market trading after Fuzzy Panda Research disclosed a short position and alleged regulatory and billing misconduct, including overbilling and potential unlawful practices. The company's stock had already declined from its 52-week high of $150.44, and broader market pressures contributed to the decline.

$BLLNMed

BillionToOne shares slide in pre-market trading following short-seller report

BillionToOne (BLLN) shares fell 6% premarket after a short-seller report alleged improper billing, undisclosed regulatory scrutiny, and clinical claim weaknesses. Fuzzy Panda Research, which holds a short position, cited FOIA records, anonymous sources, and billing data. The report claims potential EBITDA reduction of 80% and False Claims Act penalties up to $1.2B. BillionToOne has not responded.

$BLLNMed

BillionToOne: Q3 Earnings Snapshot

BillionToOne (BLLN) reported Q3 earnings of $17.4M, or 32 cents per share, beating estimates of 16 cents. Revenue was $123M, exceeding forecasts of $116.2M. The company expects full-year revenue between $460M and $470M. Shares have risen 39% YTD.